1. Funder, JW, Carey, RM, Mantero, F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889–1916.
Google Scholar | Crossref | Medline | ISI2. Rossi, G, Boscaro, M, Ronconi, V, et al. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005; 16: 104–107.
Google Scholar | Crossref | Medline3. Wu, VC, Chueh, SJ, Chen, L, et al. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years. J Hypertens 2017; 35: 1698–1708.
Google Scholar | Crossref | Medline4. Rossi, GP, Maiolino, G, Flego, A, et al. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension 2018; 71: 585–591.
Google Scholar | Crossref | Medline5. Hundemer, GL, Curhan, GC, Yozamp, N, et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diab Endocrinol 2018; 6: 51–59.
Google Scholar | Crossref | Medline6. Catena, C, Colussi, G, Nadalini, E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80–85.
Google Scholar | Crossref | Medline7. Reincke, M, Fischer, E, Gerum, S, et al. Observational study mortality in treated primary aldosteronism: the German Conn’s registry. Hypertension 2012; 60: 618–624.
Google Scholar | Crossref | Medline8. Funder, JW, Carey, RM, Fardella, C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266–3281.
Google Scholar | Crossref | Medline | ISI9. Nishikawa, T, Omura, M, Satoh, F, et al. Guidelines for the diagnosis and treatment of primary aldosteronism—the Japan Endocrine Society 2009. Endocr J 2011; 58: 711–721.
Google Scholar | Crossref | Medline | ISI10. Higgins, JPT, Thomas, J, Chandler, J, et al. Cochrane handbook for systematic reviews of interventions. version 6.2 (updated February 2021). Cochrane, 2021, www.training.cochrane.org/handbook
Google Scholar11. Wells, GA, Shea, B, O’Connell, D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 20 April 2018).
Google Scholar12. Liberati, A, Altman, DG, Tetzlaff, J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
Google Scholar | Crossref13. DerSimonian, R, Laird, N. Meta-analysis in clinical trials revisited. Contemp Clin Trials 2015; 45: 139–145.
Google Scholar | Crossref | Medline | ISI14. Higgins, JP, Thompson, SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–1558.
Google Scholar | Crossref | Medline | ISI15. DerSimonian, R, Laird, N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.
Google Scholar | Crossref | Medline16. Mantel, N, Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719–748.
Google Scholar | Medline17. Demets, DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med 1987; 6: 341–350.
Google Scholar | Crossref | Medline | ISI18. Su, PF, Chen, X, Chen, H, et al. Statistical aspects of omics data analysis using the random compound covariate. BMC Syst Biol 2012; 6(Suppl 3): S11.
Google Scholar | Crossref19. Egger, M, Davey Smith, G, Schneider, M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.
Google Scholar | Crossref | Medline20. Wallace, BC, Schmid, CH, Lau, J, et al. Meta-analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol 2009; 9: 80.
Google Scholar | Crossref | Medline | ISI21. Chen, YY, Lin, YH, Huang, WC, et al. Adrenalectomy improves the long-term risk of end-stage renal disease and mortality of primary aldosteronism. J Endocr Soc 2019; 3: 1110–1126.
Google Scholar | Crossref | Medline22. Kunzel, HE, Apostolopoulou, K, Pallauf, A, et al. Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone. J Psychiatr Res 2012; 46: 1650–1654.
Google Scholar | Crossref | Medline23. Mulatero, P, Monticone, S, Bertello, C, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab 2013; 98: 4826–4833.
Google Scholar | Crossref | Medline24. Monticone, S, D’Ascenzo, F, Moretti, C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diab Endocrinol 2018; 6: 41–50.
Google Scholar | Crossref | Medline25. Iacobellis, G, Petramala, L, Cotesta, D, et al. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J Clin Endocrinol Metab 2010; 95: 2391–2398.
Google Scholar | Crossref | Medline26. Petramala, L, Pignatelli, P, Carnevale, R, et al. Oxidative stress in patients affected by primary aldosteronism. J Hypertens 2014; 32: 2022–2029.
Google Scholar | Crossref | Medline27. Petramala, L, Iacobellis, G, Carnevale, R, et al. Enhanced soluble serum CD40L and serum P-selectin levels in primary aldosteronism. Horm Metab Res 2016; 48: 440–445.
Google Scholar | Crossref | Medline28. Frustaci, A, Letizia, C, Verardo, R, et al. Primary aldosteronism-associated cardiomyopathy: clinical-pathologic impact of aldosterone normalization. Int J Cardiol 2019; 292: 141–147.
Google Scholar | Crossref | Medline29. Williams, TA, Lenders, JWM, Mulatero, P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diab Endocrinol 2017; 5: 689–699.
Google Scholar | Crossref | Medline30. Fallo, F, Pilon, C, Urbanet, R. Primary aldosteronism and metabolic syndrome. Horm Metab Res 2012; 44: 208–214.
Google Scholar | Crossref | Medline31. Rossi, GP, Cesari, M, Cuspidi, C, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013; 62: 62–69.
Google Scholar | Crossref | Medline32. Mulatero, P, Bertello, C, Rossato, D, et al. Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. J Clin Endocrinol Metab 2008; 93: 1366–1371.
Google Scholar | Crossref | Medline